Sam Altman's Longevity Startup Develops Anti-Aging Brain Pill





Unlocking the Secrets to Extended Youth: A New Era in Longevity Research
Advancing the Fight Against Cognitive Decline: Retro Biosciences' Novel Pill
Retro Biosciences, a prominent venture supported by Sam Altman, is preparing to launch its inaugural clinical trial for an experimental medication known as RTR242. This pill is specifically engineered to address Alzheimer's disease by revitalizing the body's natural cellular recycling processes. Joe Betts-LaCroix, the CEO of Retro Biosciences, views this as a crucial step towards decoupling aging from its associated ailments and cognitive deterioration.
The Visionary Behind Retro Biosciences: Joe Betts-LaCroix's Pursuit of Paradigm Shifts
Joe Betts-LaCroix, a distinguished scientist and entrepreneur, is leading Retro Biosciences with an ambition to revolutionize our understanding of aging. His past innovations, including the creation of the world's smallest computer, reflect his commitment to radical advancements. At Retro, he is channeling this passion into extending the human healthspan, aiming to achieve a significant shift in how we perceive and experience the aging process.
Pioneering a New Approach to Healthspan Extension
With an initial investment of $180 million from Sam Altman, Retro Biosciences is poised to begin its first clinical trials by late 2025. The company's primary objective is to enhance the healthy human lifespan by a decade, focusing on treatments that actively reverse biological aging. This ambitious goal sets Retro apart in the longevity field, which often concentrates on merely slowing down the aging process.
RTR242: A Promising Solution for Brain Health and Beyond
The experimental drug, RTR242, is designed to reactivate autophagy, a vital cellular mechanism responsible for removing damaged proteins and cellular waste. This process, often impaired with age, is critical for preventing neurodegenerative conditions like Alzheimer's. By restoring efficient cellular clean-up, RTR242 aims to improve brain function and contribute to a healthier aging experience. The initial safety trials are slated to commence in Australia due to streamlined regulatory pathways.
Strategic Growth and Ambitious Funding Goals
To support its expansive research and development, Retro Biosciences is seeking to raise an additional $1 billion in its Series A funding round. This substantial capital would enable the company to expand its clinical trials and solidify its position among leading longevity startups, such as Altos Labs, which has attracted billions in investment from tech luminaries.
Innovation Beyond the Pill: Comprehensive Anti-Aging Strategies
Beyond RTR242, Retro Biosciences is actively developing other pioneering therapies. These include RTR890, a treatment for blood disorders like leukemia that involves generating fresh blood stem cells from a patient's own biological material. Additionally, RTR888 is a stem cell-derived therapy targeting central nervous system diseases. Each of these initiatives shares the overarching goal of rejuvenating biological systems to a more youthful state.
Distinguishing Retro's Approach from Traditional Alzheimer's Treatments
Unlike existing Alzheimer's medications, which primarily aim to decelerate cognitive decline by reducing amyloid plaques, Retro's RTR242 strives for a more transformative outcome. By focusing on reversing cellular damage through enhanced autophagy, the company seeks to fundamentally restore brain health. Betts-LaCroix emphasizes a preference for therapies that reverse aging, considering those that merely slow it down as less impactful.
Bridging Conventional and Revolutionary Pharmaceutical Methods
The longevity sector is characterized by two distinct methodologies: a cautious, disease-specific approach favored by traditional pharmaceutical companies, and a bolder, more transformative "moonshot" strategy. Retro Biosciences endeavors to combine both, developing targeted treatments like RTR242 while also pursuing more radical biological resets. This dual approach aims to deliver both immediate therapeutic benefits and long-term, systemic anti-aging effects.
The AI-Powered Future of Longevity Research
Retro Biosciences is also leveraging cutting-edge technology, including a custom GPT-4b micro developed in partnership with OpenAI. This AI-powered protein design tool has demonstrated remarkable capabilities in enhancing stem cell reprogramming markers, accelerating research into cellular rejuvenation. While the full potential of AI in anti-aging treatments is still being explored, it promises to be a transformative force in the field. Despite the ambitious technological frontiers, Retro maintains a pragmatic and cautious stance in its clinical trial methodology.